Correct Answer: A. Adenylyl cyclase
Beta-2 adrenergic receptors are G-protein coupled receptors (specifically Gs-coupled) that mediate metabolic effects including hyperglycemia. When epinephrine or norepinephrine binds to β2 receptors, the activated Gs protein directly stimulates adenylyl cyclase, which catalyzes the conversion of ATP to cyclic AMP (cAMP). This increased intracellular cAMP activates protein kinase A (PKA), which phosphorylates and activates hormone-sensitive lipase and glycogen phosphorylase, leading to glycogenolysis and lipolysis. In the pancreas, β2 stimulation inhibits insulin secretion (via cAMP-mediated mechanisms), contributing to hyperglycemia. Conversely, β2 blockade (as with non-selective beta-blockers like propranolol) can mask hypoglycemia symptoms and impair glucose recovery in diabetic patients—a critical safety concern in Indian clinical practice where beta-blockers are widely used for hypertension and cardiac disease. The adenylyl cyclase–cAMP–PKA axis is the canonical β2-mediated signaling pathway for all metabolic effects, making it the discriminating answer.
Why the other options are wrong
B. Phospholipase C — Phospholipase C is the downstream effector of Gq-coupled receptors (e.g., α1-adrenergic, muscarinic M1/M3, angiotensin II receptors), not β2 receptors. PLC generates IP3 and DAG, mediating calcium mobilization and PKC activation—mechanisms unrelated to β2-mediated glucose metabolism. This is a common trap confusing different G-protein signaling pathways. C. Guanylyl cyclase — Guanylyl cyclase produces cyclic GMP (cGMP) and is activated by nitric oxide and natriuretic peptides, not adrenergic receptors. While cGMP has vasodilatory effects, it plays no role in β2-mediated hyperglycemia or glucose homeostasis. This option exploits confusion between different second-messenger systems. D. Phospholipase A2 — Phospholipase A2 releases arachidonic acid from membrane phospholipids, leading to eicosanoid synthesis (prostaglandins, leukotrienes). While some adrenergic effects involve PLA2, it is not the primary mediator of β2-induced hyperglycemia. The cAMP pathway is the canonical and rate-limiting mechanism for metabolic effects.
High-Yield Facts
- β2 receptors → Gs-coupled → adenylyl cyclase → ↑cAMP → PKA activation is the canonical pathway for hyperglycemia and metabolic effects.
- Non-selective beta-blockers (propranolol, atenolol) block β2-mediated cAMP production, masking hypoglycemia symptoms and impairing glucose recovery in Indian diabetic patients on insulin/sulfonylureas.
- β2 stimulation in pancreatic islets inhibits insulin secretion via cAMP-PKA, directly contributing to hyperglycemia independent of hepatic glycogenolysis.
- Adenylyl cyclase is the rate-limiting enzyme in β2 signaling; its inhibition by Gi-coupled receptors (α2, M2, adenosine A1) explains counter-regulatory effects on glucose metabolism.
- Selective β2 agonists (salbutamol, terbutaline) can cause transient hyperglycemia in Indian asthma/COPD patients due to adenylyl cyclase activation and reduced insulin secretion.
Mnemonics
Gs → cAMP → Hyperglycemia Gs-coupled β2 → Adenylyl cyclase → cAMP → Protein kinase A → Glycogenolysis + ↓Insulin = Hyperglycemia. Use when recalling β2 metabolic effects. Beta-Blocker Trap in Diabetes Non-selective beta-blockers block β2 → ↓cAMP → ↓glucose recovery + masked hypoglycemia symptoms. Selective β1-blockers (metoprolol, atenolol at low doses) are safer in Indian diabetic patients. Remember: propranolol = danger in diabetes.
NBE Trap
NBE pairs β2 receptors with multiple second-messenger enzymes (PLC, guanylyl cyclase, PLA2) to exploit confusion between Gs, Gq, and other G-protein pathways. Students who memorize "adrenergic = multiple pathways" without anchoring to the primary Gs-cAMP axis fall for distractors.
Clinical Pearl
In Indian clinical practice, a diabetic patient on insulin presenting with recurrent hypoglycemic episodes may be masked by propranolol (non-selective beta-blocker), delaying recognition and recovery. Switching to a selective β1-blocker (e.g., metoprolol) restores the ability to sense and counter hypoglycemia via β2-mediated cAMP-driven glucose mobilization—a critical safety adjustment in our high-burden diabetes population.
_Reference: Guyton & Hall Physiology Ch. 61 (Adrenergic Receptors); KD Tripathi Pharmacology Ch. 10 (Adrenergic Agonists & Antagonists); Harrison Principles of Internal Medicine Ch. 72 (Catecholamines & Sympathomimetic Drugs)_